Literature DB >> 24002059

Small-molecule inhibitor of the Shigella flexneri master virulence regulator VirF.

Veerendra Koppolu1, Ichie Osaka, Jeff M Skredenske, Bria Kettle, P Scott Hefty, Jiaqin Li, Susan M Egan.   

Abstract

VirF is an AraC family transcriptional activator that is required for the expression of virulence genes associated with invasion and cell-to-cell spread by Shigella flexneri, including multiple components of the type three secretion system (T3SS) machinery and effectors. We tested a small-molecule compound, SE-1 (formerly designated OSSL_051168), which we had identified as an effective inhibitor of the AraC family proteins RhaS and RhaR, for its ability to inhibit VirF. Cell-based reporter gene assays with Escherichia coli and Shigella, as well as in vitro DNA binding assays with purified VirF, demonstrated that SE-1 inhibited DNA binding and transcription activation (likely by blocking DNA binding) by VirF. Analysis of mRNA levels using real-time quantitative reverse transcription-PCR (qRT-PCR) further demonstrated that SE-1 reduced the expression of the VirF-dependent virulence genes icsA, virB, icsB, and ipaB in Shigella. We also performed eukaryotic cell invasion assays and found that SE-1 reduced invasion by Shigella. The effect of SE-1 on invasion required preincubation of Shigella with SE-1, in agreement with the hypothesis that SE-1 inhibited the expression of VirF-activated genes required for the formation of the T3SS apparatus and invasion. We found that the same concentrations of SE-1 had no detectable effects on the growth or metabolism of the bacterial cells or the eukaryotic host cells, respectively, indicating that the inhibition of invasion was not due to general toxicity. Overall, SE-1 appears to inhibit transcription activation by VirF, exhibits selectivity toward AraC family proteins, and has the potential to be developed into a novel antibacterial agent.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002059      PMCID: PMC3811841          DOI: 10.1128/IAI.00919-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  95 in total

1.  A branch in the ToxR regulatory cascade of Vibrio cholerae revealed by characterization of toxT mutant strains.

Authors:  G A Champion; M N Neely; M A Brennan; V J DiRita
Journal:  Mol Microbiol       Date:  1997-01       Impact factor: 3.501

2.  Assessment of the Alamar Blue assay for cellular growth and viability in vitro.

Authors:  G R Nakayama; M C Caton; M P Nova; Z Parandoosh
Journal:  J Immunol Methods       Date:  1997-05-26       Impact factor: 2.303

3.  Shigella actin-based motility in the absence of vinculin.

Authors:  M B Goldberg
Journal:  Cell Motil Cytoskeleton       Date:  1997

4.  Effect of O side-chain length and composition on the virulence of Shigella flexneri 2a.

Authors:  R C Sandlin; M B Goldberg; A T Maurelli
Journal:  Mol Microbiol       Date:  1996-10       Impact factor: 3.501

Review 5.  Phylogenetic, structural and functional analyses of the LacI-GalR family of bacterial transcription factors.

Authors:  C C Nguyen; M H Saier
Journal:  FEBS Lett       Date:  1995-12-18       Impact factor: 4.124

6.  A role for H-NS in the thermo-osmotic regulation of virulence gene expression in Shigella flexneri.

Authors:  M E Porter; C J Dorman
Journal:  J Bacteriol       Date:  1994-07       Impact factor: 3.490

7.  Measurement of invasion by gentamicin resistance.

Authors:  E A Elsinghorst
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

8.  A bacterial invasin induces macrophage apoptosis by binding directly to ICE.

Authors:  Y Chen; M R Smith; K Thirumalai; A Zychlinsky
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

9.  Role of the heat shock protein DnaJ in the lon-dependent degradation of naturally unstable proteins.

Authors:  Y Jubete; M R Maurizi; S Gottesman
Journal:  J Biol Chem       Date:  1996-11-29       Impact factor: 5.157

10.  The secretion of the Shigella flexneri Ipa invasins is activated by epithelial cells and controlled by IpaB and IpaD.

Authors:  R Ménard; P Sansonetti; C Parsot
Journal:  EMBO J       Date:  1994-11-15       Impact factor: 11.598

View more
  20 in total

1.  Narrow-spectrum inhibitors of Campylobacter jejuni flagellar expression and growth.

Authors:  Jeremiah G Johnson; Caroline Yuhas; Thomas J McQuade; Martha J Larsen; Victor J DiRita
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 2.  Virulence regulons of enterotoxigenic Escherichia coli.

Authors:  George P Munson
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 3.  Applications and perspectives of nanomaterials in novel vaccine development.

Authors:  Yingbin Shen; Tianyao Hao; Shiyi Ou; Churan Hu; Long Chen
Journal:  Medchemcomm       Date:  2017-10-17       Impact factor: 3.597

4.  3-Substituted Biquinolinium Inhibitors of AraC Family Transcriptional Activator VirF from S. flexneri Obtained Through In Situ Chemical Ionization of 3,4-Disubstituted Dihydroquinolines.

Authors:  Prashi Jain; Jiaqin Li; Patrick Porubsky; Benjamin Neuenswander; Susan M Egan; Jeffrey Aubé; Steven Rogers
Journal:  RSC Adv       Date:  2014-01-01       Impact factor: 3.361

Review 5.  On the road to structure-based development of anti-virulence therapeutics targeting the type III secretion system injectisome.

Authors:  Bronwyn J E Lyons; Natalie C J Strynadka
Journal:  Medchemcomm       Date:  2019-06-20       Impact factor: 3.597

Review 6.  Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.

Authors:  Jason Munguia; Victor Nizet
Journal:  Trends Pharmacol Sci       Date:  2017-03-08       Impact factor: 14.819

Review 7.  Zika virus outbreak: a review of neurological complications, diagnosis, and treatment options.

Authors:  Veerendra Koppolu; T Shantha Raju
Journal:  J Neurovirol       Date:  2018-02-13       Impact factor: 2.643

8.  The bacterial type III secretion system as a target for developing new antibiotics.

Authors:  Andrew C McShan; Roberto N De Guzman
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

9.  Burkholderia pseudomallei type III secretion system cluster 3 ATPase BsaS, a chemotherapeutic target for small-molecule ATPase inhibitors.

Authors:  Lan Gong; Shu-Chin Lai; Puthayalai Treerat; Mark Prescott; Ben Adler; John D Boyce; Rodney J Devenish
Journal:  Infect Immun       Date:  2015-01-20       Impact factor: 3.441

Review 10.  Streptococcus pyogenes ("Group A Streptococcus"), a Highly Adapted Human Pathogen-Potential Implications of Its Virulence Regulation for Epidemiology and Disease Management.

Authors:  Nikolai Siemens; Rudolf Lütticken
Journal:  Pathogens       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.